Skip to content
value.today

Harpoon Therapeutics, Inc.

Total raised
$220 M
4 rounds on record
Latest round
$100 M
Oct 2023
First round on record
May 2017
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Harpoon Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2023$100 MNo. 4$50 to $250 million

Harpoon Therapeutics, Inc.: Raise no. 4, Oct 2023

Investors in this round

18 investors had bought by the notice of Oct 31, 2023: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Harpoon Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
$6,377,484
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Julie Eastland · Executive Officer, Director
  • Luke Walker · Executive Officer
  • Andrew Robbins · Director
  • Jonathan Drachman · Director
  • Joseph Bailes · Director
  • Lauren Silvernail · Director
  • Mark Chin · Director
  • Ronald Hunt · Director
  • Scott Myers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in CA, CT, FL, MA, NJ, NY
  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, CT, FL, MA, NJ, NY
  • Canaccord Genuity LLC (CRD 1020) · New York, New YorkSold in CA, CT, FL, MA, NJ, NY

Signed by Julie Eastland, President and CEO. Newest notice filed Oct 31, 2023. Read the notice at the SEC.

equity, optionsSEC
Mar 2023$25 MNo. 3$10 to $50 million

Harpoon Therapeutics, Inc.: Raise no. 3, Mar 2023

Investors in this round

6 investors had bought by the notice of Apr 7, 2023: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Harpoon Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: 8.000% Series A Redeemable Preferred Stock and Warrants to Purchase Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Julie Eastland · Executive Officer, Director
  • Luke Nathaniel Walker · Executive Officer
  • Alan Colowick · Director
  • Andrew Robbins · Director
  • Joanne P. Viney · Director
  • Jonathan Drachman · Director
  • Joseph Bailes · Director
  • Lauren P. Silvernail · Director
  • Mark Chin · Director
  • Ronald Hunt · Director
  • Scott Myers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The Company intends to use the net proceeds to complete its ongoing clinical studies, working capital and other general corporate purposes.”

Signed by Julie Eastland, President and Chief Executive Officer. Newest notice filed Apr 7, 2023. Read the notice at the SEC.

equity, optionsSEC
Nov 2018$70 MNo. 2$50 to $250 million

Harpoon Therapeutics, Inc.: Raise no. 2, Nov 2018

Investors in this round

17 investors had bought by the notice of Nov 26, 2018: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Harpoon Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$70 M of $70 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Georgia L. Erbez · Executive Officer · Chief Financial Officer
  • Gerald McMahon · Executive Officer, Director · President and CEO
  • Holger R. Wesche · Executive Officer · Chief Scientific Officer
  • Natalie R. Sacks · Executive Officer · Chief Medical Officer
  • Jonathan R. Drachman · Director
  • Julie R. Eastland · Director
  • Luke R. Evnin · Director
  • Mark R. Chin · Director
  • Patrick R. Baeuerle · Director
  • Ron R. Hunt · Director
  • Scott R. Myers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher Whitmore, Secretary and Vice President, Finance. Newest notice filed Nov 26, 2018. Read the notice at the SEC.

equitySEC
May 2017$25 MNo. 1$10 to $50 million

Harpoon Therapeutics, Inc.: Raise no. 1, May 2017

Investors in this round

7 investors had bought by the notice of Jun 6, 2017: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Harpoon Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $45 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gerald McMahon · Executive Officer, Director
  • William E. Picht · Executive Officer
  • Dan E. Hicklin · Director
  • Luke E. Evnin · Director
  • Mark E. Chin · Director
  • Pablo E. Cagnoni · Director
  • Patrick E. Baeuerle · Director
  • Ron E. Hunt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William E. Picht, Jr., Chief Financial Officer. Newest notice filed Jun 6, 2017. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Harpoon Therapeutics, Inc. had revenue between $5 million and $25 million when it filed its newest notice of a funding round (Oct 2023).

    SEC Form D (revenue range) · Oct 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2023

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

18 named in official filings. Open an investor to see everything it has backed.

Investors in Harpoon Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Arix Bioscience Holdings LtdCompanynot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Arix Bioscience PLCCompanynot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MPM Asset Management Investors BV2014 LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MPM Asset Management LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MPM Bioimpact LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MPM BioVentures 2014 (B), L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MPM BioVentures 2014 GP LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MPM BioVentures 2014 LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MPM BioVentures 2014, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
MPM Oncology Impact Management GP LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
New Leaf Biopharma Opportunities II, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2023)SEC Form 3
New Leaf BPO Associates II, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2023)SEC Form 3
New Leaf BPO Management II, L.L.CFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2023)SEC Form 3
New Leaf Venture Associates III, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2023)SEC Form 3
New Leaf Venture Management III, L.L.C.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2023)SEC Form 3
New Leaf Ventures III, L.P.Venture capitalnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Oncology Impact Fund (Cayman) Management L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3
UBS Oncology Impact Fund L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Harpoon Therapeutics, Inc.
NameRoleNamed in
Julie EastlandExecutive officerOct 2023
Luke WalkerExecutive officerOct 2023
Luke Nathaniel WalkerExecutive officerApr 2023
Georgia L. ErbezChief Financial OfficerNov 2018
Gerald McMahonPresident and CEONov 2018
Holger R. WescheChief Scientific OfficerNov 2018
Natalie R. SacksChief Medical OfficerNov 2018
William E. PichtExecutive officerJun 2017
Andrew RobbinsDirectorOct 2023
Jonathan DrachmanDirectorOct 2023
Joseph BailesDirectorOct 2023
Julie EastlandDirectorOct 2023
Lauren SilvernailDirectorOct 2023
Mark ChinDirectorOct 2023
Ronald HuntDirectorOct 2023
Scott MyersDirectorOct 2023
Alan ColowickDirectorApr 2023
Joanne P. VineyDirectorApr 2023
Lauren P. SilvernailDirectorApr 2023
Gerald McMahonPresident and CEONov 2018
Jonathan R. DrachmanDirectorNov 2018
Julie R. EastlandDirectorNov 2018
Luke R. EvninDirectorNov 2018
Mark R. ChinDirectorNov 2018
Patrick R. BaeuerleDirectorNov 2018
Ron R. HuntDirectorNov 2018
Scott R. MyersDirectorNov 2018
Dan E. HicklinDirectorJun 2017
Luke E. EvninDirectorJun 2017
Mark E. ChinDirectorJun 2017
Pablo E. CagnoniDirectorJun 2017
Patrick E. BaeuerleDirectorJun 2017
Ron E. HuntDirectorJun 2017